FDA Warning Letter Explorer
Medical Devices · Letter issue date: Nov 22, 2024

Argon Medical Productions & Vertrieb Gesellschaft MBH & CO

3 extracted findings · 3 model-assigned issue types

FDA source excerpt, selected passage

Complaints involving potential device failures, such as the failure of dental implants to osseointegrate, were not investigated as required.

Findings and supporting evidence

Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.

Complaints & adverse event reporting21 CFR 820.198(c)

Complaints involving potential device failures, such as osseointegration failure, were not investigated as required.

Supporting FDA text
Source excerpt · automated text-match check

Complaints involving potential device failures, such as the failure of dental implants to osseointegrate, were not investigated as required.

Complaints & adverse event reporting21 CFR 803.17(a)(1)

The MDR procedure lacks internal systems for timely identification, communication, and evaluation of reportable events.

Supporting FDA text
Source excerpt · automated text-match check

The procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1).

Complaints & adverse event reporting21 CFR 803.17(a)(3)

The MDR procedure lacks internal systems for timely transmission of complete medical device reports.

Supporting FDA text
Source excerpt · automated text-match check

The procedure does not establish internal systems that provide for timely transmission of complete medical device reports, as required by 21 CFR 803.17(a)(3).

Complaints & adverse event reporting21 CFR 803.50(a)(1)

The firm failed to submit MDR reports within 30 days for serious injuries involving osseointegration failure.

Supporting FDA text
Source excerpt · automated text-match check

Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).

Labeling, claims & marketing21 CFR 801.20(a)

Labels of K3Pro Kronus Dental implant devices do not bear a unique device identifier (UDI).

Supporting FDA text
Source excerpt · automated text-match check

The labels of the K3Pro Kronus Dental implant devices do not bear such a UDI.

Labeling, claims & marketing21 CFR 801.40(a)(1)

The K3Pro XP-Line device label lacks UDI in easily readable plain-text.

Supporting FDA text
Source excerpt · automated text-match check

there is no UDI presented in easily readable plain-text on the label of the K3Pro Rapid (Ref 40009K3PRO.R), K3Pro XP-Line (Ref BSP.XP 35020/3), and K3Pro S-line (Ref 45011K3PRO.S) (see 21 CFR 801.40(a)(1))

Labeling, claims & marketing21 CFR 801.40(a)(2)

The K3Pro XP-Line device label lacks UDI in machine-readable form using AIDC technology.

Supporting FDA text
Source excerpt · automated text-match check

there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of K3Pro XP-Line (Ref BSP.XP 35020/3) (see 21 CFR 801.40(a)(2))

Registration, listing & premarket21 CFR 830.300(a)

The firm failed to submit required information to GUDID for the K3Pro XP-Line devices.

Supporting FDA text
Source excerpt · automated text-match check

has not submitted to GUDID information required by 21 CFR Part 830, subpart E, respecting these devices.

Findings extracted from the letter

Selected FDA passages, not the complete letter.

01
Failure to review, evaluate, and investigate any complaint involving the possible failure of a device, labeling, or package to meet any of its specification unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). For example:
02
Failure to adequately develop, maintain, and implement written MDR procedures as required by 21 CFR 803.17(a). For example, during the inspection, your firm acknowledged the procedure Post Market Surveillance procedure A002 as its written MDR procedure, and agreed with the investigator that the procedure have the following deficiencies:
03
Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1).

What FDA requested

Model-assisted summary. Consult the letter for complete requests and conditions.

  • Provide documentation and evidence of corrective actions for complaint handling, including revised process instructions, work instructions, and forms.
  • Provide English-translated documents for the revised MDR procedure (AA_002) and evidence of staff training.
  • Provide documentation of the retrospective review of complaints from the past two years to assess reportability under MDR requirements.
  • Provide documentation of corrections and/or corrective actions for UDI labeling and GUDID submission.
  • Provide a translation of documentation not in English to facilitate review.

Sections and clauses cited

As cited in this historical letter, not a statement of current regulatory requirements.

Keep exploring

More medical-device letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.